Influx Healthtech Limited · NSE:INFLUX
Influx Healthtech — H1 FY27 Earnings Presentation
36 slides from Influx Healthtech's earnings presentation, Nov 5, 2026
Slide 1: Submission letter to NSE for investor presentation
November 5, 2026 To, Listing Department, National Stock Exchange Limited Exchange Plaza, C-1, Block-G, Bandra Kurla Complex, Bandra (E), Mumbai-400 051 Scrip Code – INFLUX Dear Sir/Ma’am, Sub.: Submission of Investor Presentation for Investor Conference Call scheduled to be held on November 5, 2026.
Slide 2: Investor Presentation – H1 FY27 Earnings Update
INVESTOR PRESENTATION – H1 FY27 EARNINGS UPDATE
Slide 3: Agenda
Agenda 1. Performance Update 2. About Influx Healthtech Limited 3. Competitive Moats 4. Investment Rationale 5. Historical Business Performance 6. Select Financial Statement Data 7. Annexures
Slide 4: Executive Summary – H1 FY27
Executive Summary – H1 FY27 Revenue & Profitability Return & Capital Presence & Capacity Revenue from Operations Return on Equity (RoE) Product Range INR 85.4 crs. 21.4% 2,345 Up 28% YoY Vs 20.4% in FY26 Vs 3,428 in FY26 EBITDA Return on Capital Employed (RoCE) Client Retention INR 18.3 crs. 28.1% 9
Slide 5: Performance Update & Management Commentary – H1 FY27
Performance Update & Management Commentary – H1 FY27 ▪ Successfully completed the installation of additional automated bar lines, enabling the production of multilayer wafer bars. ▪ Completed machine installation for the newly introduced Ready-to-Drink (RTD) blister shots. Business Updates ▪ Further
Slide 6: Revenue Split Across Segments
Revenue Split Across Segments (₹ crores) Nutraceuticals Cosmetics Ayurvedic Others1 6.9 1.1 75.3 2.7 60.1 3.4 2.1 0.5 H1 FY26 H1 FY27 H1 FY26 H1 FY27 H1 FY26 H1 FY27 H1 FY26 H1 FY27 1% 1% 88% 90% 4% H1 FY26 2% H1 FY27 5% 8% 1 Nutraceuticals Cosmetics Ayurvedic Others 5 1. Others include veterinary a
Slide 7: Agenda
Agenda 1. Performance Update 2. 2. About About Influx Influx Healthtech Healthtech Limited Limited 3. Competitive Moats 4. Investment Rationale 5. Historical Business Performance 6. Select Financial Statement Data 7. Annexures
Slide 8: Formulation Driven, Brand Focused Healthcare Company
Formulation Driven, Brand Focused Healthcare Company About Influx Healthtech Limited Revenue Mix – H1 FY27 (%) ▪ Founded in 2020 by Dr. Munir Chandniwala, Influx Healthtech is a contract development Ayurvedic, 2% Veterinary & Homecare, 1% and manufacturing organization (CDMO) specializing in nutrace
Slide 9: Strategic Milestones
Strategic Milestones Transitioned into a Started snacking and Became public private limited gummies production limited company company lines 2003 2021 2024 2026 2020 2023 2025 Started Entered industry manufacturing units Acquired additional Introduced "Quick Snap" for nutraceuticals, land in Palghar
Slide 10: Agenda
Agenda 1. Executive Summary 2. About Influx Healthtech Limited 3. 3. Competitive Competitive moats Moats 4. Investment Rationale 5. Historical Business Performance 6. Select Financial Statement Data 7. Annexures
Slide 11: Sustainable Competitive Moats
Sustainable Competitive Moats Well-Diversified Product Portfolio Formulation Driven Innovation Robust & Integrated Business Model Strong Clientele Across Geographies & Industries Capacity Expansion For Sustained Growth Industry Leading Certification & Compliance Systems Passionate & Purpose-Driven T
Slide 12: Well-Diversified Product Portfolio
Well-Diversified Product Portfolio Home Care Dietary/Nutritional Supplements Veterinary Feeds 0.0% 1.3% 88.2% 85.4crs. H1 FY27 revenue 2.4% Ayurvedic /Herbal 8.1% Cosmetics Our product lines reflect our dedication to bringing cutting edge, science-backed health solutions to consumers Note: Chart is
Slide 13: Actively Focused on Expanding Our Product Portfolio
Actively Focused on Expanding Our Product Portfolio 2026 • Quick snapTM technology • MMTC technology 2025 • Functional beverages 2024 • Pet food for cats • Ayurvedic gummies • Nutritional oral gel 2021 2023 • Oral dissolving powder • Pet food for dogs • Nutritional gummies 2022 • Wafer protein bars
Slide 14: In-House F&D Unit: Key Driver in Creating Innovative Solutions
In-House F&D Unit: Key Driver in Creating Innovative, Market-Ready Solutions ▪ Provide development services including formulation development, process development and analytical development ▪ In-house formulation & development (F&D) team focused on creating new formulations based on current health t
Slide 15: Supporting Clients Across all Stages of Development & Manufacturing
Supporting Clients Across all Stages of Development & Manufacturing Contact Influx Sample Preparation Label Designing Finished Healthtech Product New Product Idea Pricing Finalizing Packaging Commercial Scale Production 14
Slide 16: Strong Clientele Across Geographies & Industries
Strong Clientele Across Geographies & Industries Number of Clients Marquee Clients 718 636 538 559 523 FY23 FY24 FY25 FY26 H1 FY27 Develop reliable, palatable formulations that ensure consumer acceptance and long-term client success Work closely with clients to refine formulations for feasibility, c
Slide 17: Capacity Expansion for Sustained Growth
Capacity Expansion for Sustained Growth Nutraceuticals Cosmetics & Ayurvedic Pet Supplements & Homecare Capacity Utilization: 85% Capacity Utilization: 60% Capacity Utilization: 65% 1,000 5,000 300 22,000 4,150 2,100 17,000 3,150 1,800 FY26 Addition H1 FY27 FY26 Addition H1 FY27 FY26 Addition H1 FY2
Slide 18: Massive Increase in Output Post Commissioning of Our New Capacity
Massive Increase in Output Post Commissioning of Our New Capacity Unit – 1 Nutraceuticals Unit – 2 Cosmetics & ayurvedic Incremental Capacities Commercialized in H1FY27, Through Internal Accruals & IPO Funds Multi-Line Production ▪ 250 kg/day: Tablet production ▪ 35,000 bottles/shift: Liquid product
Slide 19: Capex Deployment Progressing as Planned
Capex Deployment Progressing as Planned Unit – 1 Nutraceuticals Unit – 2 CosmeticsMachinery & ayurvedicReceived | Funded via IPO Proceeds Automated Beverage Manufacturing Line (Testing in Process) ▪ Capacity: 10,000 bottles/hour ▪ Supports both carbonated and non-carbonated beverage formats Sachet C
Slide 20: Industry Leading Certification & Compliance Systems
Industry Leading Certification & Compliance Systems Industry Leading Certifications and Accreditations Enhancing our Ability to Further Revenue Growth Adherence to High Quality Standards Prevents unsafe food from reaching consumers Reduces risks like contamination, errors, or unsafe products Builds
Slide 21: Awards & Recognition
Awards & Recognition 2015 2016 2016 2018 2025 Best Nutraceutical Company of Best Sports Supplement Best Sports Supplement Innovative Nutraceuticals Grade A+ Exemplar the Year 2015 in 3rd Party Manufacturing Company of the Manufacturing Company of the of the Year, 2018. Certification, 2025. Certified
Slide 22: Passionate & Purpose-Driven Team
Passionate & Purpose-Driven Team Dr. M.A. Chandniwala Mrs. Shirin Chandniwala Dr. A.A. Chandniwala Dr. Vipul Patel CA Mohmad Saleh Mutvalli MD & Chairman Whole-time Director Director Independent Director Independent Director Industry Experience: 22+ years Industry Experience: 12+ years Industry Expe
Slide 23: Agenda
Agenda 1. Executive Summary 2. About Influx Healthtech Limited 3. Competitive Moats 4. 4.Investment Investmentrationale Rationale 5. Historical Business Performance 6. Select Financial Statement Data 7. Annexures
Slide 24: Investment Rationale: Influx Healthtech Limited
Investment Rationale: Influx Healthtech Limited Diversified Product Portfolio Wide-Ranging Client Base Advanced Formulation Development Multi-nutritional tablets, dietary A strong presence across cosmetics, supplements, ayurvedic products, oral Specializes in formulation pharmaceuticals, and homecar
Slide 25: Agenda
Agenda 1. Executive Summary 2. About Influx Healthtech Limited 3. Competitive Moats 4. Investment Rationale 5. 2. Historical 5. About business Influx Historical performance Healthtech Business Limited Performance 6. Select Financial Statement Data 7. Annexures
Slide 26: Historic Business Performance (1/3)
Historic Business Performance (1/3) Revenue from Revenue from Operations operations (₹ (₹ crs.) crs.) RevenueEBITDA from operations (₹ crs.) (₹ crs.) Revenue from PAToperations (₹ crs.) (₹ crs.) 147 30 21 100 105 21 85 17 18 13 11 12 FY24 FY25 FY26 H1 FY27 FY24 FY25 FY26 H1 FY27 FY24 FY25 FY26 H1 FY
Slide 27: Historic Business Performance (2/3)
Historic Business Performance (2/3) Revenue fromROE operations 1 (₹ crs.) Revenue from operations Debtor Days (₹ crs.) RevenueInventory from operations Days (₹ crs.) 113 49% 112 124 84 99 37% 72 58 20% 21% 41 FY24 FY25 FY26 H1 FY27 FY24 FY25 FY26 H1 FY27 FY24 FY25 FY26 H1 FY27 RevenueAsset from oper
Slide 28: Historic Business Performance (3/3)
Historic Business Performance (3/3) Revenue fromConcentration Revenue operations (₹1 crs.) Revenue fromConcentration Supplier operations (₹1 crs.) Revenue Cash Flowfrom fromoperations Operations(₹ (₹crs.) crs.) 50% 39% 36% 9 49% 29% 7 7 49% 20% 48% 4 FY24 FY25 FY26 H1 FY27 FY24 FY25 FY26 H1 FY27 FY2
Slide 29: Agenda
Agenda 1. Executive Summary 2. About Influx Healthtech Limited 3. Competitive Moats 4. Investment Rationale 5. Historical Business Performance 2. 6.About Select Influx Healthtech Financial financial Limited Statement statement Data data 7. Annexures
Slide 30: Income Statement
Income Statement ₹ Crores Unless Otherwise Mentioned Particulars H1 FY27 H1 FY26 YoY change (%) Revenue from operations 85.4 66.8 27.9% Cost of materials consumed including finished goods and WIP 50.8 37.5 35.4% Employee benefits expense 6.6 5.1 29.0% Other expenses 9.7 9.5 2.3% Total operating expe
Slide 31: Balance Sheet
Balance Sheet ₹ Crores Unless Otherwise Mentioned Assets H1FY27 FY26 FY25 PPE and intangible assets 34.4 27.6 18.8 Capital work-in-progress 15.0 3.5 0.0 Non-current assets 10.5 11.2 2.5 Cash and cash equivalents 9.6 25.2 1.9 Current investments 5.5 2.3 0.0 Short term loans and advances 8.3 3.9 0.8 T
Slide 32: Cashflow Statement
Cashflow Statement ₹ Crores Unless Otherwise Mentioned Cashflow From Operating Activities H1FY27 FY26 FY25 Net Profit before tax & extraordinary items 16.2 27.2 17.7 Depreciation & amortization expenses 2.3 3.8 2.8 Other adjustment 0.1 -0.6 0.2 Trade receivables -0.4 -1.8 -16.6 Trade payables 5.1 -1
Slide 33: Annexures: Industry Outlook
Agenda 1. Executive Summary 2. About Influx Healthtech Limited 3. Competitive Moats 4. Investment Rationale 5. Historical Business Performance 6. Select Financial Statement Data 7. 7. Annexures Annexures: Industry Outlook
Slide 34: India's CDMO Industry to Grow 2x Global Industry
India’s CDMO Industry to Grow 2x Global Industry Global CDMO Industry (In $ bn) Levers Driving Growth of India’s CDMO Industry 278 7.2% CAGR Strategic Shift Toward Outsourcing ▪ Pharma firms outsource to CDMOs for cost savings and expertise, with CDMOs offering end-to-end drug development services C
Slide 35: India's Nutraceutical Industry: $76 BN Opportunity
India’s Nutraceutical Industry: $76 BN Opportunity Global nutraceutical Industry (In $ bn) Growth Drivers of India’s Nutraceutical Industry 919 7.6% CAGR Lifestyle Shifts With Rising Health Consciousness ▪ Rising health awareness and lifestyle changes are driving demand for nutraceuticals 591 Suppor
Slide 36: Thank You
Thank You For any further information/factory visit request, please contact: Company Investor relations consultant Influx Healthtech Ltd. Capital Bridge Advisory Service Private Ltd Mr. Ashish Shah, CFO Mr. Raj Shah, CFA Mr. Hrishit Jhaveri, CFA cs@influxhealthtech.com raj@capbridge.in hrishit@capbr